Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT

BASEL, Switzerland, Aug. 27, 2024 /PRNewswire/ — Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announces positive results from its randomized, double-blind, dose-finding placebo-controlled Proof-of-Concept (POC) clinical trial in patients suffering from HHT.      HHT, an Orphan Disease, is the second […] L'articolo Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT proviene da La Ragione.

CONTINUA A LEGGERE